Macrophage heterogeneity in the context of rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 12, Issue 8, 2016, Pages 472-485

  Udalova, Irina A ^a   Mantovani, Alberto ^b   Feldmann, Marc ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON REGULATORY FACTOR 5; ONCOPROTEIN; PROTO-ONCOGENE PROTEIN SPI-1; TRANSACTIVATOR PROTEIN;

CELL INFILTRATION; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE MODEL; DRUG TARGETING; ENVIRONMENTAL FACTOR; EPIGENETICS; HEMATOPOIESIS; HUMAN; INFLAMMATION; MACROPHAGE; MACROPHAGE FUNCTION; MONOCYTE; MOUSE; NONHUMAN; ONTOGENY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; TRANSCRIPTION REGULATION; ANIMAL; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; DRUG DISCOVERY; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HUMANS; MACROPHAGES; MOLECULAR TARGETED THERAPY; MONOCYTES; PROTO-ONCOGENE PROTEINS; SYNOVIAL MEMBRANE; TRANS-ACTIVATORS;

EID: 84978062481     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2016.91     Document Type: Review

References (137)

1. Takasugi, K., & Hollingsworth, J. W. Morphologic studies of mononuclear cells of human synovial fluid. Arthritis Rheum. 10, 495-501 (1967).
2. Cooper, N. S., Soren, A., McEwen, C., & Rosenberger, J. L. Diagnostic specificity of synovial lesions. Hum. Pathol. 12, 314-328 (1981).
3. Janossy, G., et al. Rheumatoid arthritis: A disease of T lymphocyte/macrophage immunoregulation. Lancet 2, 839-842 (1981).
4. Bottazzo, G. F., Pujol-Borrell, R., Hanafusa, T., & Feldmann, M. Role of aberrant HLA DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 2, 1115-1119 (1983).
5. Feldmann, M., & Maini, R. N. Lasker Clinical Medical Research Award. TNF defined as A therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9, 1245-1250 (2003).
6. Chu, C. Q., Field, M., Feldmann, M., & Maini, R. N. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1125-1132 (1991).
7. McInnes, I. B., & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429-442 (2007).
8. Feldmann, M., Brennan, F. M., & Maini, R. N. Rheumatoid arthritis. Cell 85, 307-310 (1996).
9. Wright, H. L., Moots, R. J., & Edwards, S. W. The multifactorial role of neutrophils in rheumatoid arthritis. Nat. Rev. Rheumatol. 10, 593-601 (2014).
10. Murphy, C. A., et al. Divergent pro-And antiinflammatory roles for IL 23 and IL 12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951-1957 (2003).
11. Miossec, P., & Kolls, J. K. Targeting IL 17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11, 763-776 (2012).
12. Shigeyama, Y., et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 43, 2523-2530 (2000).
13. Hamilton, J. A., Filonzi, E. L., & Ianches, G. Regulation of macrophage colony-stimulating factor (M CSF) production in cultured human synovial fibroblasts. Growth Factors 9, 157-165 (1993).
14. Yoshida, H., et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345, 442-444 (1990).
15. Dougall, W. C., et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424 (1999).
16. Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D., & Mundy, G. R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319, 516-518 (1986).
17. Lam, J., et al. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488 (2000).
18. Sims, N. A., & Gooi, J. H. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin. Cell Dev. Biol. 19, 444-451 (2008).
19. Redlich, K., & Smolen, J. S. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat. Rev. Drug Discov. 11, 234-250 (2012).
20. Koch, A. E., et al. Synovial tissue macrophage as A source of the chemotactic cytokine IL 8. J. Immunol. 147, 2187-2195 (1991).
21. Koch, A. E., et al. Enhanced production of monocyte chemoattractant protein 1 in rheumatoid arthritis. J. Clin. Invest. 90, 772-779 (1992).
22. Leizer, T., Cebon, J., Layton, J. E., & Hamilton, J. A. Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM CSF and G CSF production by interleukin 1 and tumor necrosis factor. Blood 76, 1989-1996 (1990).
23. Hamilton, J. A. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8, 533-544 (2008).
24. Tak, P. P., & Bresnihan, B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 43, 2619-2633 (2000).
25. Haringman, J. J., et al. Synovial tissue macrophages: A sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64, 834-838 (2005).
26. Barrera, P., et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 43, 1951-1959 (2000).
27. Ginhoux, F., et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841-845 (2010).
28. Schulz, C., et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86-90 (2012).
29. Epelman, S., et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 40, 91-104 (2014).
30. Yona, S., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79-91 (2013).
31. Hoeffel, G., et al. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with A minor contribution of yolk sac-derived macrophages. J. Exp. Med. 209, 1167-1181 (2012).
32. Merad, M., et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat. Immunol. 3, 1135-1141 (2002).
33. Bain, C. C., et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat. Immunol. 15, 929-937 (2014).
34. Tamoutounour, S., et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity 39, 925-938 (2013).
35. Sieweke, M. H., & Allen, J. E. Beyond stem cells: self-renewal of differentiated macrophages. Science 342, 1242974 (2013).
36. Gautier, E. L., et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13, 1118-1128 (2012).
37. Geissmann, F., et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 656-661 (2010).
38. De Kleer, I., Willems, F., Lambrecht, B., & Goriely, S. Ontogeny of myeloid cells. Front. Immunol. 5, 423 (2014).
39. Kumaravelu, P., et al. Quantitative developmental anatomy of definitive haematopoietic stem cells/ long-Term repopulating units (HSC/RUs): role of the aorta-gonad-mesonephros (AGM) region and the yolk sac in colonisation of the mouse embryonic liver. Development 129, 4891-4899 (2002).
40. Kieusseian, A., Brunet de la Grange, P., Burlen-Defranoux, O., Godin, I., & Cumano, A. Immature hematopoietic stem cells undergo maturation in the fetal liver. Development 139, 3521-3530 (2012).
41. Sheng, J., Ruedl, C., & Karjalainen, K. Most tissue-resident macrophages except microglia are derived from fetal hematopoietic stem cells. Immunity 43, 382-393 (2015).
42. Hoeffel, G., et al. C Myb+ erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 42 665-678 2015).
43. Calderon, B., et al. The pancreas anatomy conditions the origin and properties of resident macrophages. J. Exp. Med. 212, 1497-1512 (2015).
44. Wilson, A., et al. c Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 18, 2747-2763 (2004).
45. Manz, M. G., & Boettcher, S. Emergency granulopoiesis. Nat. Rev. Immunol. 14, 302-314 (2014).
46. Swirski, F. K., Hilgendorf, I., & Robbins, C. S. From proliferation to proliferation: monocyte lineage comes full circle. Semin. Immunopathol. 36, 137-148 (2014).
47. Sathe, P., et al. Lymphoid tissue and plasmacytoid dendritic cells and macrophages do not share A common macrophage-dendritic cell-restricted progenitor. Immunity 41, 104-115 (2014).
48. Hettinger, J., et al. Origin of monocytes and macrophages in A committed progenitor. Nat. Immunol. 14, 821-830 (2013).
49. Naik, S. H., et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat. Immunol. 8, 1217-1226 (2007).
50. Onai, N., et al. Identification of clonogenic common Flt3+M CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat. Immunol. 8, 1207-1216 (2007).
51. Swirski, F. K., et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612-616 (2009).
52. Leuschner, F., et al. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J. Exp. Med. 209, 123-137 (2012).
53. Geissmann, F., Jung, S., & Littman, D. R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19, 71-82 (2003).
54. Boring, L., et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C C chemokine receptor 2 knockout mice. J. Clin. Invest. 100, 2552-2561 (1997).
55. Serbina, N. V., & Pamer, E. G. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 7, 311-317 (2006).
56. Croxford, A. L., et al. The cytokine GM CSF drives the inflammatory signature of CCR2 monocytes and licenses autoimmunity. Immunity 43, 502-514 (2015).
57. Auffray, C., et al. Monitoring of blood vessels and tissues by A population of monocytes with patrolling behavior. Science 317, 666-670 (2007).
58. Ziegler-Heitbrock, L., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 116, e74-e80 (2010).
59. Ingersoll, M. A., et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 115, e10-e19 (2010).
60. Martinez, F. O., Gordon, S., Locati, M., & Mantovani, A. Transcriptional profiling of the human monocyte-To macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177, 7303-7311 (2006).
61. Jakubzick, C., et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 39, 599-610 (2013).
62. Rodero, M. P., et al. Immune surveillance of the lung by migrating tissue monocytes. eLife 4, e07847 (2015).
63. Molawi, K., et al. Progressive replacement of embryo-derived cardiac macrophages with age. J. Exp. Med. 211, 2151-2158 (2014).
64. van de Laar, L., et al. Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissue-resident macrophages. Immunity 44, 755-768 (2016).
65. Nerlov, C., & Graf, T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev. 12, 2403-2412 (1998).
66. Olson, M. C., et al. PU. 1 is not essential for early myeloid gene expression but is required for terminal myeloid differentiation. Immunity 3, 703-714 (1995).
67. Mossadegh-Keller, N., et al. M CSF instructs myeloid lineage fate in single haematopoietic stem cells. Nature 497, 239-243 (2013)
68. Alder, J. K., et al. Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo. J. Immunol. 180, 5645-5652 (2008).
69. Feinberg, M. W., et al. The Kruppel-like factor KLF4 is A critical regulator of monocyte differentiation. EMBO J. 26, 4138-4148 (2007).
70. Laslo, P., et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 126, 755-766 (2006).
71. Barozzi, I., et al. Coregulation of transcription factor binding and nucleosome occupancy through DNA features of mammalian enhancers. Mol. Cell 54, 844-857 (2014).
72. Ghisletti, S., et al. Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity 32, 317-328 (2010).
73. Heinz, S., et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
74. Gosselin, D., & Glass, C. K. Epigenomics of macrophages. Immunol. Rev. 262, 96-112 (2014).
75. Tamura, T., Nagamura-Inoue, T., Shmeltzer, Z., Kuwata, T., & Ozato, K. ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity 13, 155-165 (2000).
76. Mancino, A., et al. A dual cis-regulatory code links IRF8 to constitutive and inducible gene expression in macrophages. Genes Dev. 29, 394-408 (2015).
77. Rosas, M., et al. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science 344, 645-648 (2014).
78. Okabe, Y., & Medzhitov, R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157, 832-844 (2014).
79. Schneider, C., et al. Induction of the nuclear receptor PPAR γ by the cytokine GM CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. Nat. Immunol. 15, 1026-1037 (2014).
80. Gosselin, D., et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 159, 1327-1340 (2014).
81. Lavin, Y., et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312-1326 (2014).
82. Ostuni, R., et al. Latent enhancers activated by stimulation in differentiated cells. Cell 152, 157-171 (2013).
83. Garber, M., et al. A high-Throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. Mol. Cell 47, 810-822 (2012).
84. Krausgruber, T., et al. IRF5 promotes inflammatory macrophage polarization and TH1 TH17 responses. Nat. Immunol. 12, 231-238 (2011).
85. Weiss, M., Blazek, K., Byrne, A. J., Perocheau, D. P., & Udalova, I. A. IRF5 is A specific marker of inflammatory macrophages in vivo. Mediators Inflamm. 2013, 245804 (2013).
86. Saliba, D. G., et al. IRF5:RelA interaction targets inflammatory genes in macrophages. Cell Rep. 8, 1308-1317 (2014).
87. Murray, P. J., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14-20 (2014).
88. O?Neill, L. A., & Pearce, E. J. Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 213, 15-23 (2016).
89. Recalcati, S., Locati, M., Gammella, E., Invernizzi, P., & Cairo, G. Iron levels in polarized macrophages: regulation of immunity and autoimmunity. Autoimmun. Rev. 11, 883-889 (2012).
90. Wang, N., Liang, H., & Zen, K. Molecular mechanisms that influence the macrophage M1-M2 polarization balance. Front. Immunol. 5, 614 (2014).
91. Gordon, S., & Martinez, F. O. Alternative activation of macrophages: mechanism and functions. Immunity 32, 593-604 (2010).
92. Mantovani, A., Sica, A., & Locati, M. Macrophage polarization comes of age. Immunity 23, 344-346 (2005).
93. Lawrence, T., & Natoli, G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 11, 750-761 (2011).
94. Xue, J., et al. Transcriptome-based network analysis reveals A spectrum model of human macrophage activation. Immunity 40, 274-288 (2014).
95. Gentek, R., Molawi, K., & Sieweke, M. H. Tissue macrophage identity and self-renewal. Immunol. Rev. 262, 56-73 (2014).
96. Yeadon, C., & Karsh, J. Lymphapheresis in rheumatoid arthritis. The clinical and laboratory effects of A limited course of cell depletion. Clin. Exp. Rheumatol. 1, 119-124 (1983).
97. Hahn, G., et al. Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. J. Clin. Invest. 91, 862-870 (1993).
98. Salisbury, A. K., Duke, O., & Poulter, L. W. Macrophage-like cells of the pannus area in rheumatoid arthritic joints. Scand. J. Rheumatol. 16, 263-272 (1987).
99. Cauli, A., Yanni, G., & Panayi, G. S. Interleukin 1, interleukin 1 receptor antagonist and macrophage populations in rheumatoid arthritis synovial membrane. Br. J. Rheumatol. 36, 935-940 (1997).
100. Ambarus, C. A., Noordenbos, T., de Hair, M. J., Tak, P. P., & Baeten, D. L. Intimal lining layer macrophages but not synovial sublining macrophages display an IL 10 polarized-like phenotype in chronic synovitis. Arthritis Res. Ther. 14, R74 (2012).
101. Kennedy, A., Fearon, U., Veale, D. J., & Godson, C. Macrophages in synovial inflammation. Front. Immunol. 2, 52 (2011).
102. Ye, L., et al. Interleukin 10 attenuation of collagen-induced arthritis is associated with suppression of interleukin 17 and retinoid-related orphan receptor ?t production in macrophages and repression of classically activated macrophages. Arthritis Res. Ther. 16, R96 (2014).
103. De Rycke, L., et al. Differential expression and response to anti-TNFα treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J. Pathol. 206, 17-27 (2005).
104. Asquith, D. L., Miller, A. M., McInnes, I. B., & Liew, F. Y. Animal models of rheumatoid arthritis. Eur. J. Immunol. 39, 2040-2044 (2009).
105. Bruhns, P., Samuelsson, A., Pollard, J. W., & Ravetch, J. V. Colony-stimulating factor-1 dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18, 573-581 (2003).
106. Misharin, A. V., et al. Nonclassical Ly6C-monocytes drive the development of inflammatory arthritis in mice. Cell Rep. 9, 591-604 (2014).
107. Weiss, M., et al. IRF5 controls both acute and chronic inflammation. Proc. Natl Acad. Sci. USA 112, 11001-11006 (2015).
108. Rafei, M., et al. An engineered GM CSF-CCL2 fusokine is A potent inhibitor of CCR2 driven inflammation as demonstrated in A murine model of inflammatory arthritis. J. Immunol. 183, 1759-1766 (2009).
109. Pr?sumey, J., et al. Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis. Ann. Rheum. Dis. 72, 1717-1724 (2013).
110. Li, J., et al. Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in A humanized death receptor mouse model. Arthritis Rheum. 64, 1098-1109 (2012).
111. Bróhl, H., et al. Targeting of Gr 1+,CCR2+ monocytes in collagen-induced arthritis. Arthritis Rheum. 56, 2975-2985 (2007).
112. Quinones, M. P., et al. Experimental arthritis in CC chemokine receptor 2 null mice closely mimics severe human rheumatoid arthritis. J. Clin. Invest. 113, 856-866 (2004).
113. Rossol, M., Kraus, S., Pierer, M., Baerwald, C., & Wagner, U. The CD14bright CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum. 64, 671-677 (2012).
114. Scott, D. L., Wolfe, F., & Huizinga, T. W. Rheumatoid arthritis. Lancet 376, 1094-1108 (2010).
115. Semerano, L., et al. Targeting IL 6 for the treatment of rheumatoid arthritis: phase II investigational drugs. Expert Opin. Investig. Drugs 23, 979-999 (2014).
116. van Roon, J. A., et al. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fc? receptor I directed immunotoxin. Arthritis Rheum. 48, 1229-1238 (2003).
117. van Vuuren, A. J., et al. CD64 directed immunotoxin inhibits arthritis in A novel CD64 transgenic rat model. J. Immunol. 176, 5833-5838 (2006).
118. U.S. Food & Drug Administration. FDA approves new therapy for certain types of advanced soft tissue sarcoma. http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm468832.htm (2015).
119. Germano, G., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249-262 (2013).
120. Getts, D. R., et al. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci. Transl. Med. 6, 219ra217 (2014).
121. Vergunst, C. E., et al. Modulation of CCR2 in rheumatoid arthritis: A double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 58, 1931-1939 (2008).
122. Lebre, M. C., et al. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis. PLoS ONE 6, e21772 (2011).
123. Greven, D. E., et al. Preclinical characterisation of the GM CSF receptor as A therapeutic target in rheumatoid arthritis. Ann. Rheum. Dis. 74, 1924-1930 (2015).
124. Burmester, G. R., Feist, E., & Dorner, T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 10, 77-88 (2014).
125. Burmester, G. R., et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann. Rheum. Dis. 72, 1445-1452 (2013).
126. Genovese, M. C., et al. Results from A phase IIA parallel group study of JNJ 40346527, an oral CSF 1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy. J. Rheumatol. 42, 1752-1760 (2015).
127. Campbell, I. K., Rich, M. J., Bischof, R. J., & Hamilton, J. A. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M CSF and G CSF and requirement for endogenous M CSF. J. Leukoc. Biol. 68, 144-150 (2000).
128. Duffau, P., et al. Promotion of inflammatory arthritis by interferon regulatory factor 5 in A mouse model. Arthritis Rheumatol. 67, 3146-3157 (2015).
129. Hamilton, J. A., & Achuthan, A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol. 34, 81-89 (2013).
130. Courties, G., et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J. Am. Coll. Cardiol. 63, 1556-1566 (2014).
131. Jain, S., Tran, T. H., & Amiji, M. Macrophage repolarization with targeted alginate nanoparticles containing IL 10 plasmid DNA for the treatment of experimental arthritis. Biomaterials 61, 162-177 (2015).
132. Shalek, A. K., et al. Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. Nature 510, 363-369 (2014).
133. Jaitin, D. A., et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 343, 776-779 (2014).
134. Bendall, S. C., et al. Single-cell mass cytometry of differential immune and drug responses across A human hematopoietic continuum. Science 332, 687-696 (2011).
135. Schwanhusser, B., et al. Global quantification of mammalian gene expression control. Nature 473, 337-342 (2011).
136. Becher, B., et al. High-dimensional analysis of the murine myeloid cell system. Nat. Immunol. 15, 1181-1189 (2014).
137. Jaitin, D. A., Keren-Shaul, H., Elefant, N., & Amit, I. Each cell counts: hematopoiesis and immunity research in the era of single cell genomics. Semin. Immunol. 27, 67-71 (2015).